Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
The claims based on inventions from the results from our EEG/fMRI target engagement study are both novel and unexpected and will strengthen
"When approved by USPTO these patent's will further strengthen our drug products and market position, giving
About GT-002
GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing. An EEG/fMRI target engagement study in healthy volunteers aimed to determine the effects of GT-002 on brain activity across different brain regions and neuronal networks has recently been completed.
Contact Information
Phone: 073-687 28 39
E-mail: mrw@gabather.com
About
For more information, please visit: www.gabather.com
Certified Adviser
Phone: +4672-252 34 51
Email: ca@corpura.se
www.corpura.se
Forward-looking statement
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Public/11735/3946912/b5e635e909a537a0.pdf |
PM patent application 2024-03-18 |
View original content:https://www.prnewswire.co.uk/news-releases/gabather-files-two-new-patent-applications-to-secure-novel-findings-on-the-effects-of-gt-002-for-the-treatment-of-psychiatric-disorders-302091220.html